AbbVie Inc. (ABBV) Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDT
Company Participants
Scott Reents – Executive VP & CFO
Roopal Thakkar – Executive VP of Research & Development and Chief Scientific Officer
Conference Call Participants
Jason Gerberry – BofA Securities, Research Division
Presentation
Jason Gerberry
BofA Securities, Research Division
All right. Great. We’re going to get going here with our next company presenter at the BofA Global Healthcare Conference here in Nevada or Las Vegas. So thank you.
We’ve got the AbbVie team and Scott Reents EVP, CFO; and Roopal Thakkar, Research and Development and CSO. My name is Jason Gerberry. I cover pharma and biotech at Bank of America. And so I’ve got a discussion that I think is a good mix of CFO questions and R&D questions because I know that there’s a lot to hit on here.
Question-and-Answer Session
Jason Gerberry
BofA Securities, Research Division
Maybe my first question for you, Scott, is just thinking about the P&L and you’ve — you guys are in a great place in terms of having a long LOE runway. And you’re still pretty bullish about the growth that your core engines can provide Skyrizi and Rinvoq. And so I think consensus estimates, an incremental $15 billion of revenue, I think, by 2031 on Skyrizi and Rinvoq. So maybe talk about operating leverage dynamics because you’re at such a high watermark from a revenue perspective. And I can’t imagine there’s a lot of incremental investment to support the brands from here. But maybe I’m wrong. And the reason I ask is, I look at Street op margins kind of topping at 52% and that was kind of where op margins topped the year before HUMIRA went LOE. So I’m just sort of curious, do you think that there is a potential upside to how the Street is modeling the operating leverage in the
Credit: Source link
